Bolt Biotherapeutics (BOLT) IPO Opens 31% Higher
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Today's IPO for Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) opened for trading at $26.10 after pricing 11,500,000 shares of common stock at a price to the public of $20.00 per share.
Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities are acting as joint bookrunners for the offering.
BOLT is a a clinical-stage immuno-oncology company
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Brazilian Card Network Elo Choses Goldman Sachs, JPMorgan And Morgan Stanley For IPO - Reuters
- Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001
- Sports streaming service DAZN weighs IPO to drive fresh growth